Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer

Abstract excerpt

Oncogenic mutations in the BRAF kinase occur in 6-8% of nonsmall cell lung cancers (NSCLCs), accounting for more than 90,000 deaths annually worldwide. The biological and clinical relevance of these BRAF mutations in NSCLC is incompletely understood. Here we demonstrate that human NSCLC cells with BRAF(V600E), but not other BRAF mutations, initially are sensitive to BRAF-inhibitor treatment. However, these...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Lung Cancer Treatments and Mutations
• Share to Melanoma and MAPK Pathways
• Share to Protein Tyrosine Phosphatases